🟢 BeyondSpring is trading 9% up; no company-specific catalyst identified

BeyondSpring is trading 9.01% up at $0.84 on September 30, 2026, with no new company-specific announcement identified to explain the morning move.

• On September 29, the company reported FDA Fast Track designation for plinabulin plus docetaxel and a strategic transaction to advance the Phase 3 DUBLIN-4 trial.
• That news preceded the sharp prior-session decline and does not clearly explain today’s rebound.